XML 76 R66.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock Option and Grant Plan - Additional Information (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Feb. 29, 2020
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Oct. 31, 2019
May 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Stock-based compensation expense   $ 22,209,000 $ 12,968,000 $ 61,822,000 $ 28,068,000    
Weighted-average grant date fair value per share of options granted       $ 41.84      
Stock Options              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Unrecognized compensation expense related to unvested stock options   148,500,000   $ 148,500,000      
Unrecognized compensation cost, cost to recognize over a weighted-average period       2 years 4 months 24 days      
Restricted Stock              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Unrecognized compensation cost, cost to recognize over a weighted-average period       3 years 2 months 12 days      
Unrecognized stock-based compensation expense, expected to vest   $ 98,300,000   $ 98,300,000      
Restricted Stock | Maximum              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Vesting period       4 years      
Restricted Stock | Minimum              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Vesting period       2 years      
2017 Plan | Stock Options and Restricted Stock | Common Stock              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Maximum number of shares for future issuance             8,078,681
2019 Plan              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Maximum number of shares for future issuance           3,700,000  
Number of shares reserved for future issuance   10,947,167   10,947,167      
Number of shares available for future issuance   1,703,263   1,703,263      
2019 Plan | Common Stock | Maximum              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Annual percentage increase in shares authorized       4.00%      
2019 Plan | Including 2017 Plan Shares | Maximum              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Maximum number of shares for future issuance           5,639,818  
2019 Employee Stock Purchase Plan              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Number of shares available for future issuance   1,665,199   1,665,199      
Number of shares issued   41,083   70,073 0    
Stock-based compensation expense   $ 200,000 $ 0 $ 1,100,000 $ 0    
Common stock, shares description       In February 2020, the Company’s board of directors adopted the Beam Therapeutics Inc. 2019 Employee Stock Purchase Plan, or ESPP, which was approved by the Company’s stockholders. Pursuant to the ESPP, certain employees of the Company, excluding consultants and non-employee directors, are eligible to purchase common stock of the Company at a reduced rate during offering periods. The ESPP permits participants to purchase common stock using funds contributed through payroll deductions, subject to a calendar year limit of $25,000 and at a purchase price of 85% of the lower of the fair market value of the Company’s common stock on the first trading day of the offering period or on the applicable purchase date, which will be the final trading day of the applicable purchase period. The ESPP has two annual purchase periods extending from October to March and April to September.      
Maximum amount allowed to purchase common stock using payroll deduction $ 25,000            
Percentage of common stock purchase price lower of the fair market value 85.00%